Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY) ("Tilray"), a global leader in medical cannabis, today announced the acquisition of HelloMD Corporation, a digital healthcare and patient engagement platform that expands Tilray’s direct-to-patient capabilities, creates a fully vertically integrated medical cannabis framework for Tilray in Canada, and advances its global medical cannabis growth strategy. Tilray was the successful bidder in HelloMD’s formal sale process and plans to acquire HelloMD’s Canadian medical cannabis assets following formal Court approval on June 29, 2026.

The acquisition will strengthen Tilray’s global medical cannabis platform by expanding direct-to-patient capabilities, enhancing physician and patient education, and deepening engagement across the care journey, while establishing an integrated Canadian framework that connects quality cultivation, clinical expertise, practitioner support, product access, and fulfillment.

As medical cannabis becomes a more established part of healthcare, Tilray is building an integrated care model that supports patients from education and physician consultations to product access, fulfillment, and ongoing support. Historically, medical cannabis has often been considered later in a patient’s care journey. With the appropriate resources and clinical support, HelloMD provides Tilray with a platform to help engage eligible patients earlier through education, practitioner access, and trusted guidance, expanding awareness of regulated, plant-based medical cannabis options as part of a broader approach to natural health and wellness.

HelloMD has supported hundreds of thousands of patients through telehealth consultations, educational resources, and personalized medical cannabis guidance. Its platform complements Tilray’s global healthcare infrastructure, including EU-GMP certified cultivation and manufacturing, pharmaceutical distribution through CC Pharma, medical cannabis clinics, digital pharmacy capabilities, and patient access platforms across North America, Europe, Australia, and other international markets.

Blair MacNeil, President, Tilray Canada, said, "Medical cannabis is becoming a more integrated part of healthcare, and patients are looking for trusted, convenient access to care supported by education and guidance. By combining HelloMD’s digital healthcare platform with Tilray’s medical cannabis portfolio, clinical expertise, and national fulfillment capabilities, we are creating a more connected pathway for patients and healthcare practitioners in Canada. This acquisition establishes a fully vertically integrated medical cannabis framework for Tilray in Canada while strengthening our broader global platform, expanding patient engagement, practitioner support, and access in regulated medical markets. As adoption continues to grow, Tilray is well positioned to serve patients with high-quality medical cannabis solutions and healthcare services across the continuum of care."

Larry Lisser, CEO, HelloMD, added, "From day one, our mission at HelloMD has been to make medical cannabis more accessible through innovative technology, approachable education, and trusted healthcare experiences. I’m incredibly proud of what our team built alongside our healthcare practitioners and business partners, and of how we scaled together to deliver meaningful outcomes for patients. I believe Tilray has the expertise, infrastructure, and drive to expand the platform’s reach and impact, benefiting patients for years to come."

The acquisition is expected to enhance Tilray’s ability to deliver a more seamless patient experience, generate insights that support education and engagement, and expand access in regulated medical markets globally.

Tilray also sees an opportunity to broaden patient and consumer awareness in adjacent wellness categories, including sleep support and pain management, where over-the-counter products represent a multi-billion-dollar market in which Tilray is not meaningfully represented today. Subject to applicable regulations, Tilray intends to use HelloMD’s digital education and engagement capabilities to responsibly build awareness of regulated, plant-based medical cannabis alternatives among appropriate audiences seeking natural health solutions.

The acquisition reinforces Tilray’s commitment to advancing medical cannabis through innovation, patient engagement, scientific leadership, expanded global access, and the continued strengthening of HelloMD Corporation’s existing strategic partnerships to ensure continuity of care and sustained value for patients and healthcare practitioners. As Tilray grows its international medical business, the Company remains focused on delivering high-quality medical cannabis products and healthcare solutions to patients worldwide.

Financial terms of the transaction were not disclosed.